Effects of ketamine, s-ketamine, and MK 801 on proliferation, apoptosis, and necrosis in pancreatic cancer cells

BMC Anesthesiology

Volumn 15, Issue 1, 2015, Pages

  Malsy, Manuela ^a   Gebhardt, Kristina ^a   Gruber, Michael ^a   Wiese, Christoph ^a   Graf, Bernhard ^a   Bundscherer, Anika ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

Apoptosis; Cancer; Ketamine; MK 801; Necrosis; NMDA; Pancreatic carcinoma; Proliferation; S ketamine

Indexed keywords

DIZOCILPINE; ESKETAMINE; KETAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2A; DIZOCILPINE MALEATE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; PANCREATIC CANCER CELL LINE; PROTEIN EXPRESSION; ADENOCARCINOMA; CHEMISTRY; COMPARATIVE STUDY; DRUG EFFECTS; GENETICS; NECROSIS; PANCREATIC NEOPLASMS; PATHOLOGY; STEREOISOMERISM; TUMOR CELL LINE;

ADENOCARCINOMA; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; DIZOCILPINE MALEATE; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; KETAMINE; NECROSIS; PANCREATIC NEOPLASMS; RECEPTORS, N-METHYL-D-ASPARTATE; STEREOISOMERISM;

EID: 84938203794     PISSN: None     EISSN: 14712253     Source Type: Journal    
DOI: 10.1186/s12871-015-0076-y     Document Type: Article

References (48)

1. WHO. Cancer fact sheet No 297; 2012.
2. Oberstein P, Kenneth P. Pancreatic cancer: why is it so hard to treat? Therap Adv Gastroenterol. 2013;6:321-7.
3. Vincent A, Herman J, Schulick R, Hruban R, Goggins M. Pancreatic cancer. Lancet. 2011;378:607-20.
4. Gnoni A, Licchetta A, Scarpa A, Azzariti A, Brunett A, Simone G, et al. Carcinogenesis of pancreatic adenocarcinoma: precursor lesion. Int J Mol Sci. 2013;14:19731-62.
5. Hidalgo M. Pancreatic cancer. N Engl J Med. 2010;362:1605-17.
6. Doi R, Imamura M, Hosotani R, Imaizumi T, Hatori T, Takasaki K, et al. Surgery versus radiochemotherapy for resectable locally invasive pancreatic cancer: final results of a randomized multi-institutional trial. Surg Today. 2008;38:1021-8.
7. Egberts J, Cloosters V, Noack A, Scniewind B, Thon L, Klose S, et al. Anti-tumor necrosis factor therapy inhibits pancreatic tumor growth and metastasis. Cancer Res. 2008;5:1443-50.
8. Parada-Turska J, Rzeski W, Majdan M, Kandefer-Szerszen M, Turski WA. Effect of glutamate receptor antagonists and antirheumatic drugs on proliferation of synoviocytes in vitro. Eur J Pharmacol. 2006;535:95-7.
9. Jimi N, Segawa K, Minami K, Sata T, Shigematsu A. Inhibitory effect of the intravenous anesthetic, ketamine, on rat mesangial cell proliferation. Anesth Analg. 1997;84:190-5.
10. Shiga Y, Minami K, Segawa K, Uezono Y, Shiraishi M, Sata T, et al. The inhibition of aortic smooth muscle cell proliferation by the intravenous anesthetic ketamine. Anesth Analg. 2004;99:1408-12.
11. Rzeski W, Ikonomidou C, Turski L. Glutamate antagonists limit tumor growth. Biochem Pharmacol. 2002;64:1195-200.
12. Lee S, Wu T, Yu P, Chen R. Apoptotic insults to human Hep G2 cells induced by S-(+)-ketamine occurs through activation of a Bax-mitochondra-caspase protease pathway. Br J Anaesth. 2009;102:80-9.
13. Yamaguchi F, Hirata Y, Akram H, Kamitori K, Dong Y, Sui L, et al. FOXO/TXNIP pathway is involved in the suppression of hepatocellular carcinoma growth by glutamate antagonist MK 801. BMC Cancer. 2013;13:468-79.
14. Persson J. Ketamine in pain management. CNS Neurosci Ther. 2013;19:396-402.
15. Craven R. Ketamine. Anaesthesia. 2013;1:48-53.
16. Hirota K, Lambert DG. Ketamine:its mechanism(s) of action and unusual clinical uses. Br J Anaesth. 1996;77:441-4.
17. Tawfic QA. A review of the use of ketamine in pain management. J Opioid Manag. 2013;9:379-88.
18. Bredlau AL, Thakur R, Korones DN, Dworkin RH. Ketamine for Pain in Adults and Children with cancer: a systematic Review and Synthesis of the Literature. Pain Med. 2013;14:1505-7.
19. Szczurowska E, Mares P. Glutamate, glutamate receptors and downstream signaling pathways. Int J Biol Sci. 2013;9:948-59.
20. Cull-Candy S and Leszkiew D. Role of distinct NMDA receptor subtypes at central synapses. Sci STKE. 2004;255:re16.
21. Warburton E, Barker G, Brown M. Investigations into the involvement of NMDA mechanisms in reconition memory. Neuropharmacology. 2013;74:41-7.
22. Mueller H, Meador-Woodruff J. NR3A NMDA receptor subunit mRNA expression in schizophrenia, depression and bipolar disorder. Schizophr Res. 2004;71:361-70.
23. Luksch H, Uckermann O, Stepulak A, Hendruschk S, Marzahn J, Bastian S, et al. Silencing of selected glutamate receptor subunits modulates cancer growth. Anticancer Res. 2011;10:3181-92.
24. Stepulak A, Luksch H, Gebhardt C, Uckermann O, Marzahn J, Sifringer M, et al. Expression of glutamate receptor subunits in human cancers. Histochem Cell Biol. 2009;132:435-45.
25. Stepulak A, Luksch H, Uckermann O, Sifringer M, Rzeski W, Polberg K, et al. Glutamate Receptors in Laryngeal Cancer cells. Anticancer Res. 2011;31:565-73.
26. Kalariti N, Pissimissis N, Koutsilieris M. The glutamatergic system outside the CNS and in cancer biology. Expert Opin Investig. 2005;12:1487-96.
27. Abdul M, Hoosein N. N-methyl-D-aspartate receptor in human prostate cancer. J Membr Biol. 2005;205:125-8.
28. Watanabe K, Kanno T, Oshima T, Miwa H, Tashiro C, Nishizaki T. The NMDA receptor NR2A subunit regulates proliferation of MKN45 human gastric cancer cells. Biochem Biophys Res Commun. 2008;367:487-90.
29. Kim M, Yamashita K, Baek J, Park H, Carvalho A, Osada M, et al. N-Methyl-D-aspartae receptor type 2B is epigenetically inactivated and exhibits tumor-suppressive activity in human esophageal cancer. Cancer Res. 2006;66:3409-18.
30. This is Number 30Stepulak A, Sifringer M, Rzeski W, Endesfelder S, Gratopp A, Pohl E, et al. NMDA antagonist inhibits the extracellular signal-regulated kinase pathway and supresses cancer growth. Proc Natl Acad Sci U S A. 2005;102:15605-10.
31. This is Number 31Idvall J, Ahlgren I, Aronsen K, Stenberg P. Ketamine infusions: Pharmacokonetics and clinical effects. Br J Anaesth. 1979;51:1167-73.
32. He H, Chen J, Xie WP, Cao S, Hu HY, Yang LQ, et al. Ketamine used as an acesodyne in human breast cancer therapy causes an undesirable side effect, upregulating anti-apoptosis protein Bcl-2 expression. Genet Mol Res. 2014;12:1907-15.
33. Kress HG. Mechanisms of action of ketamine. Anaesthesist. 1997;46:8-19.
34. Monteith G, Davis F, Roberts-Thomson S. Calcium channels and pumps in cancer: changes and consequences. J Biol Chem. 2012;287:31666-73.
35. Petroiano G, Osswald P. Ketamin. In: Anästhesie in Frage und Antwort. 3rd ed. Deutschand: Springerverlag; 2000. p. 99-102.
36. Bengtson C, Bading H. Nuclear calcium signaling. Adv Exp Med Biol. 2012;970:377-405.
37. Tavare A, Perry N, Benzonana L, Takata M, Ma D. Cancer recurrence after surgery: direct and indirect effects of anesthetic agents. Int J Cancer. 2012;130:1237-50.
38. Goldfarb Y, Ben-Eliyahu S. Surgery as a risk factor for breast cancer recurrence and metastasis: mediating mechanisms and clinical prophylactic approaches. Breast Dis. 2006;26:99-114.
39. Xuan W, Hankin J, Zhao H, Yao S and Ma D. The potential benefits of the use of regional anesthesia in cancer patients. Int J Cancer. 2014.
40. Chen WK, Miao C. The effect of anesthetic technique on survival in human cancers: a meta-analysis of retrospective and prospective studies. PLoS One. 2013;8:56540.
41. Werdehausen R, Braun S, Essmann F, Schulze-Osthoff K, Walczak H, Lipfert P, et al. Lidocaine induces apoptosis via the mitochondrial pathway independently of death receptor signaling. Anesthesiology. 2007;107:136-43.
42. Huang H, Benzonana L, Zhao H, Watts H, Perry N, Bevan C, et al. Prostate cancer cell malignancy via modulation of HIF-1 aα pathway with isoflurane and propofol alone and in combination. Br J Cancer. 2014;111:1338-49.
43. Basu G, Pathangey L, Tinder T, Gendler S, Mukherjee P. Mechanisms underlying the growth inhibitory effects of the cyclo-oxygenase-2 inhibitor celecoxib in human breast cancer cells. Breast Cancer Res. 2005;7:422-35.
44. Kushida A, Inada T, Shingu K. Enhancement of antitumor immunity after propofol treatment in mice. Immunopharmacol Immunotoxicol. 2007;29:477-86.
45. Bidart M, Berger F, Pelletier L. Anti-angiogenetic therapie: from theory to practice. Ann Biol Clin (Paris). 2013;71:527-35.
46. Burger J, Montserrat E. Coming full circle: 70 years of chronic lymphocytic leukemia cell redistribution, from glucocorticoids to inhibitors of B-cell receptor signalling. Blood. 2013;121:1501-9.
47. Modest D, Hiddemann W, Heinemann V. Chemotherapy of metastatic colorectal cancer. Internist. 2014;55:37-42.
48. 2+ for cancer cell proliferation and survival. Nat Rev Cancer. 2008;8:361-75.